Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 1994Expert Opinion on Investigational Drugs

Non-nucleoside reverse transcriptase inhibitors (NNRTIs)

View Full Paper
Ask AI
Bookmark
Share

Authors

Erik De ClercqErik De ClercqRega Institute for Medical Research

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Erik De Clercq (1994) studied this question.

synapsesocial.com/papers/6a70f38fe5469ee92be19d1bhttps://doi.org/10.1517/13543784.3.3.253
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication1993 · 114 citations
  2. 2[2',5'-Bis-O-(tert-butyldimethylsilyl)]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) (TSAO) derivatives of purine and pyrimidinenucleosides as potent and selective inhibitors of human immunodeficiency virus type 11992 · 56 citations
  3. 3The inhibition of human immunodeficiency virus type 1 reverse transcriptase by avarol and avarone derivatives1990 · 72 citations
  4. 45-Chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase1993 · 268 citations
  5. 5Current use of anti-HIV drugs in AIDS1993 · 21 citations